NewAmsterdam Pharma Company N.V.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-64.1M | $-48.4M | $-72.0M | $-17.4M | $-39.5M | $-16.6M | $-39.0M | $-93.8M |
| Depreciation & Amortization | $89.0K | $62.0K | $125.0K | $107.0K | $52.0K | $89.0K | $66.0K | $15.0K |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | — | $18.0M | — | — | $15.2M | — | — | $7.9M |
| Net Cash from Operating Activities | $-39.2M | $-30.6M | $-32.8M | $-37.7M | $-36.5M | $-12.5M | $-54.0M | $-54.6M |
| Investing Activities | ||||||||
| Capital Expenditures | $80.0K | $38.0K | $42.0K | $88.0K | $16.0K | $75.0K | $209.0K | $385.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | $-11.5M | — | — | $2.9M | — | — | $-385.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | — | $11.1M | — | — | $6.5M | — | — | $198.2M |
| Net Change in Cash | — | — | — | — | — | — | — | — |
| Free Cash Flow | $-39.3M | $-30.6M | $-32.8M | $-37.8M | $-36.5M | $-12.6M | $-54.2M | $-55.0M |